Express Mail No.: EV 313 841 886 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication of:

Dasseux et al.

Confirmation No.:

9219

Serial No.:

09/465,718

Art Unit:

1631

Filed:

December 17, 1999

Examiner:

Borin

For:

APOLIPOPROTEIN A-I AGONISTS

AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

Attorney Docket No: 9196-018-999

RECEIVED

OCT 0 8 2003

TECH CENTER 1600/2900

FEE TRANSMITTAL SHEET

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

The claim amendment fee has been estimated as shown below:

(Col. 1)			(Col. 2)	(Col. 3)	⊠ SMALL ENTITY			OTHER THAN A SMALL ENTITY			
CLAIMS REMAINING AFTER AMENDMENT			HIGHEST NO. PREVIOUSLY PAID	PRESENT EXTRA	RATE		ADDIT. FEE	OR	RATE		ADDIT. FEE
TOTAL	29	MINUS	62	0	x 9	\$	0.00		x 18	\$	
INDEP.	11	MINUS	3	0	x 43	\$	0.00		x 86	\$	
☐ FIRST	☐ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					\$	0.00			\$	
	*************				TOTAL	\$	0.00	OR	TOTAL	\$	

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date:

October 3, 2003

12,705

Rahul Pathak

(105.

For Laura A. Coruzzi (Reg. No. 30,742)

**PENNIE & EDMONDS** LLP 1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090

Enclosure



## Express Mail No.: EV 313 841 886 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux et al.

Confirmation No.:

9219

Serial No.:

09/465,718

Art Unit:

1631

Filed:

December 17, 1999

Examiner:

Borin

For:

APOLIPOPROTEIN A-I AGONISTS

AND THEIR USE TO TREAT

DYSLIPIDEMIC DISORDERS

Attorney Docket No: 9196-018-999

RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 **TECH CENTER 1600/2900** 

Sir:

In response to the non-final Office Action of August 26, 2003, please find enclosed the following:

A complete listing of the Claims begins on page 2 of this paper; Remarks/Arguments begin on page 6 of this paper.

Also included herewith is:

A Fee Transmittal Sheet.